Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

Search

Research

Associations between ethnicity, social contact, and pneumococcal carriage three years post-PCV10 in Fiji

Indigenous iTaukei had greater frequency and intensity of contact compared with Fijians of Indian Descent

Research

An economic case for a vaccine to prevent group A streptococcus skin infections

A vaccine that prevents GAS cellulitis and other skin infections, in addition to throat infections, would maximise its value and commercial viability

Research

Evaluation of safety and immunogenicity of a group a streptococcus vaccine candidate (mj8vax) in a randomized clinical trial

Intramuscular administration of novel acetylated peptide-protein conjugate vaccine candidate MJ8VAX was demonstrated to be safe and immunogenic

Research

Rhinovirus C is associated with wheezing and rhinovirus A is associated with pneumonia in hospitalized children in Morocco

We aimed to describe the distribution of RV species and associations between RV species and clinical features in children hospitalized with clinically severe pneumonia in Morocco

Research

Maternal antibiotic exposure during pregnancy and hospitalization with infection in offspring: a population-based cohort study

Antibiotic exposure before or during pregnancy was associated with increased risk of childhood hospitalized infections

Research

Epidemiology of invasive fungal infections in immunocompromised children; an Australian national 10-year review

Non-Aspergillus molds and non-albicans Candida contributed substantially to pediatric invasive fungal infection in our study

Research

The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology

Our review highlights similarities and differences in the application of the test-negative design that deserve further examination

Research

Clinical description and outcomes of Australian children with invasive group a streptococcal disease

Invasive group A streptococcal infection in Australian children is frequently severe and has a high long-term morbidity burden

Research

Effectiveness of Palivizumab against Respiratory Syncytial Virus: Cohort and Case Series Analysis

Palivizumab appeared effective for reducing virologically confirmed respiratory syncytial virus in this high-risk cohort

Research

Immunogenicity and Immune Memory after a Pneumococcal Polysaccharide Vaccine Booster in a High-Risk Population Primed with Pneumococcal Conjugate Vaccine

PPV is immunogenic in 9-month-old children at high risk of pneumococcal infections and does not affect the capacity to produce protective immune responses